<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853147</url>
  </required_header>
  <id_info>
    <org_study_id>E2020170</org_study_id>
    <nct_id>NCT04853147</nct_id>
  </id_info>
  <brief_title>Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery</brief_title>
  <official_title>Triple Combination of Fosaprepitant, Dexamethasone and Palonosetron Versus Combination of Dexamethasone and Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastrointestinal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative nausea and vomiting (PONV) are common in patients, especially in patients at&#xD;
      high risk. PONV may result in prolonged hospital stay and threaten patients' life. Because&#xD;
      the etiology of PONV is very complex, there is an increasing focus on combining antiemetics&#xD;
      from different classes for PONV prophylaxis. Fosaprepitant is a neurokinin-1 (NK-1) receptor&#xD;
      antagonist to prevent PONV. Palonosteron is a 5-HT3 receptor antagonist with high efficacy&#xD;
      and sustained action for PONV prophylaxis. Dexamethasone belongs to corticosteroid and also&#xD;
      has the ability to reduce the incident of PONV. This study aims to use the combination of&#xD;
      these three drugs in high-risk patients to test whether triple therapy is better than&#xD;
      combination of palonosteron and dexamethasone to prevent PONV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a prospective, randomized controlled study with blinded participant, care&#xD;
      provider, investigator, and outcomes assessor. 1154 patients aged 18 to 75 years undergoing&#xD;
      laparoscopic gastrointestinal surgery will be enrolled.Triple therapy of palonosetron and&#xD;
      dexamethasone plus fosaprepitant will be administered in the intervention group, and double&#xD;
      therapy of palonosetron and dexamethasone will be used in the control group. The anxiety of&#xD;
      patients will be evaluated. The primary outcome is proportion of participants with PONV&#xD;
      during the first 24 postoperative hours. Secondary outcomes are as follow: proportion of&#xD;
      participants with PONV,emetic episodes, nausea, with rescue antiemetic medication; the scores&#xD;
      of QOR-15; pain scores;time to first flatus after surgery; time to first defecation after&#xD;
      surgery; recovery time; health related quality of life; proportion of participants with&#xD;
      adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with PONV during the first 24 postoperative hours</measure>
    <time_frame>from operation completion to 24-hour after surgery (up to 24 hours)</time_frame>
    <description>PONV is defined as nausea, retching or vomiting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with PONV</measure>
    <time_frame>calcualted at 24-hour, 72-hour, 120-hour after surgery(daily recoreded up to 120 hours after surgery)</time_frame>
    <description>PONV is defined as nausea, retching or vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with emetic episodes</measure>
    <time_frame>calcualted at 24-hour, 72-hour, 120-hour after surgery(daily recorded up to 120 hours after surgery)</time_frame>
    <description>Emetic episodes are defined as retching or vomiting or both</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with nausea</measure>
    <time_frame>calcualted at 24-hour, 72-hour, 120-hour after surgery(daily recorded up to 120 hours after surgery)</time_frame>
    <description>Nausea is defined as a feeling of the urge to vomit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with rescue antiemetic medication</measure>
    <time_frame>calcualted at 24-hour, 72-hour, 120-hour after surgery(daily recorded up to 120 hours after surgery)</time_frame>
    <description>Rescue antiemetic medication is defined as an antiemetic (or other medication) given with the intention of relieving nausea and/or emesis, or any incidental use of a drug known to have antiemetic potential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of PONV</measure>
    <time_frame>calcualted at 24-hour, 72-hour, 120-hour after surgery(daily recorded up to 120 hours after surgery)</time_frame>
    <description>The severity of PONV is evaluated by a PONV impact scale score. Nausea intensity is scored as 1 ,2 ,3. In addition, vomiting intensity is scored as the number of vomits (0-2, or 3 if three or more vomits). Both scores together to obtain the PONV impact scale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative recovery score using 15-item quality of recovery scoring system(QoR-15) during each subsequent evaluation period (up to 120 hours)</measure>
    <time_frame>evaluated at 24-hour, 72-hour, 120-hour after surgery(up to 120 hours after surgery)</time_frame>
    <description>The QoR-15 comprises five subscales: pain, physical comfort, physical independence, psychological support, and emotional state. Each item is scored from 0 to 10, and the possible total score ranges from 0 to 150. A higher total score means better patient QoR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>evaluated at 24-hour, 72-hour, 120-hour after surgery(up to 120 hours after surgery)</time_frame>
    <description>Pain scores are evaluated by numerical rating scale(NRS) from no pain(0) to most severe pain (10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first flatus after surgery</measure>
    <time_frame>evaluated at the time of first exhaust after surgery(expected average of 3 days after surgery)</time_frame>
    <description>Time length between operation completion and the first flatus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first defecation after surgery</measure>
    <time_frame>evaluated at the time of the first defecation after surgery(expected average of 6 days after surgery</time_frame>
    <description>Time length between operation completion and the first defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to fulfill the criteria of hospital discharge (recovery time)</measure>
    <time_frame>from operation completion to fulfill the criteria of hospital discharge(expected 6 days )</time_frame>
    <description>The ideal time point for discharge, which is also considered as recovery time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>evaluated before surgery, at 120-hour and 30 days after surgery (up to 30 days）</time_frame>
    <description>Health related quality of life is measured by EQ-5D. Each EQ-5D health state can be coded into a five-digit number using the numbers 1 , 2 , and 3 to indicate the functional levels of the five dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adverse events (up to 30 days after surgery)</measure>
    <time_frame>from drug administration to 30 days (30 days)</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Concentration of materials in blood such as hormone and metabolics</measure>
    <time_frame>evaluated before surgery, at the end of surgery</time_frame>
    <description>materials in blood</description>
  </other_outcome>
  <other_outcome>
    <measure>3-year and 5-year survival rate</measure>
    <time_frame>3 years，5 years after surgery</time_frame>
    <description>survival rate in three or five years after surgery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1154</enrollment>
  <condition>C.Surgical Procedure; Gastrointestinal</condition>
  <arm_group>
    <arm_group_label>triple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triple combination of Fosaprepitant, Palonosetron and Dexamethasone were administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>double therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>double combination of Palonosetron and Dexamethasone were administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosteron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl</intervention_name>
    <description>palonosteron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissovled in 0.9% NaCl 150ml, iv.drip,</description>
    <arm_group_label>triple therapy</arm_group_label>
    <other_name>Triple therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosteron, dexamethasone, and 0.9% NaCl</intervention_name>
    <description>palonosteron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,</description>
    <arm_group_label>double therapy</arm_group_label>
    <other_name>double therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years and Age ≤75 years;&#xD;
&#xD;
          -  Scheduled for laparoscopic gastrointestinal surgical procedure with general anesthesia&#xD;
             ;&#xD;
&#xD;
          -  The score evaluated by Apfel simplified PONV risk assessment systems is ≥3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The American Society of Anesthesiologists (ASA) rating is &gt;3;&#xD;
&#xD;
          -  Severe hepatic dysfunction(the score of Child-Pugh is &gt;9);&#xD;
&#xD;
          -  With contraindications for using fosaprepitant, 5-HT3 receptor antagonist or&#xD;
             dexamethasone ;&#xD;
&#xD;
          -  Take medications with known antiemetic properties preoperatively ;&#xD;
&#xD;
          -  With mental disorder, or not be able to communicate ;&#xD;
&#xD;
          -  Pregnant women or nursing mothers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Zhao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth SunYetSen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Zhao, Doctor</last_name>
    <phone>13802435520</phone>
    <email>zhaoy47@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qingshan Huang, Bachelor</last_name>
    <phone>15622142186</phone>
    <email>huangqsh25@mail2.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Zhao</last_name>
      <phone>130802435520</phone>
      <email>zhaoy47@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Moon HY, Baek CW, Choi GJ, Shin HY, Kang H, Jung YH, Woo YC, Kim JY, Park SG. Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial. BMC Anesthesiol. 2014 Aug 10;14:68. doi: 10.1186/1471-2253-14-68. eCollection 2014.</citation>
    <PMID>25165427</PMID>
  </reference>
  <reference>
    <citation>Lim CS, Ko YK, Kim YH, Park SI, Kim JK, Kim MJ, Kim HJ. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting. Korean J Anesthesiol. 2013 Mar;64(3):212-7. doi: 10.4097/kjae.2013.64.3.212. Epub 2013 Mar 19.</citation>
    <PMID>23560185</PMID>
  </reference>
  <reference>
    <citation>DREAMS Trial Collaborators and West Midlands Research Collaborative. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial). BMJ. 2017 Apr 18;357:j1455. doi: 10.1136/bmj.j1455.</citation>
    <PMID>28420629</PMID>
  </reference>
  <reference>
    <citation>Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 2008 Aug;107(2):469-78. doi: 10.1213/ane.0b013e318172fa74. Erratum in: Anesth Analg. 2008 Oct;107(4):1405. Massuda, Edward B [corrected to Massuda, Ed B]; Rubenstein, Ed [corrected to Rubenstein, Edward]..</citation>
    <PMID>18633025</PMID>
  </reference>
  <reference>
    <citation>Gouveia de Araujo Ferreira N, Cavalcanti IL, Assad AR, Barrucand L, Braga ELC, Verçosa N. A prospective, randomized, double-blind trial to compare body weight-adjusted and fixed doses of palonosetron for preventing postoperative nausea and vomiting in obese female patients. PLoS One. 2020 Jan 14;15(1):e0227490. doi: 10.1371/journal.pone.0227490. eCollection 2020.</citation>
    <PMID>31935249</PMID>
  </reference>
  <reference>
    <citation>Wang EHZ, Sunderland S, Edwards NY, Chima NS, Yarnold CH, Schwarz SKW, Coley MA. A Single Prophylactic Dose of Ondansetron Given at Cessation of Postoperative Propofol Sedation Decreases Postoperative Nausea and Vomiting in Cardiac Surgery Patients: A Randomized Controlled Trial. Anesth Analg. 2020 Oct;131(4):1164-1172. doi: 10.1213/ANE.0000000000004730.</citation>
    <PMID>32925337</PMID>
  </reference>
  <reference>
    <citation>Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999 Sep;89(3):652-8.</citation>
    <PMID>10475299</PMID>
  </reference>
  <reference>
    <citation>Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, Jin Z, Kovac AL, Meyer TA, Urman RD, Apfel CC, Ayad S, Beagley L, Candiotti K, Englesakis M, Hedrick TL, Kranke P, Lee S, Lipman D, Minkowitz HS, Morton J, Philip BK. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg. 2020 Aug;131(2):411-448. doi: 10.1213/ANE.0000000000004833. Review. Erratum in: Anesth Analg. 2020 Nov;131(5):e241.</citation>
    <PMID>32467512</PMID>
  </reference>
  <reference>
    <citation>Amirshahi M, Behnamfar N, Badakhsh M, Rafiemanesh H, Keikhaie KR, Sheyback M, Sari M. Prevalence of postoperative nausea and vomiting: A systematic review and meta-analysis. Saudi J Anaesth. 2020 Jan-Mar;14(1):48-56. doi: 10.4103/sja.SJA_401_19. Epub 2020 Jan 6.</citation>
    <PMID>31998020</PMID>
  </reference>
  <reference>
    <citation>Hooper VD. SAMBA Consensus Guidelines for the Management of Postoperative Nausea and Vomiting: An Executive Summary for Perianesthesia Nurses. J Perianesth Nurs. 2015 Oct;30(5):377-82. doi: 10.1016/j.jopan.2015.08.009.</citation>
    <PMID>26408511</PMID>
  </reference>
  <reference>
    <citation>Apfel CC, Heidrich FM, Jukar-Rao S, Jalota L, Hornuss C, Whelan RP, Zhang K, Cakmakkaya OS. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth. 2012 Nov;109(5):742-53. doi: 10.1093/bja/aes276. Epub 2012 Oct 3.</citation>
    <PMID>23035051</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>YangZhao</investigator_full_name>
    <investigator_title>deputy director</investigator_title>
  </responsible_party>
  <keyword>postoperative nausea and vomiting, fosaprepitant,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 18, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT04853147/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

